• Home
• About Us
  • Overview
  • Management
  • Board of Directors
  • Dynavax Europe
  • Careers
• Pipeline
  • Overview
  • Hepatitis B Vaccine
  • Hepatitis C
  • Hepatitis B
  • Asthma
  • Autoimmunity / Inflammation
  • Flu Vaccine
• Partners
• Technology
  • Immune System
  • ISS
  • IRS
  • Publications
• Investors
  • Overview
  • News & Events
  • Stock Information
  • Analyst Coverage
  • Financials
  • SEC Filings
  • Corporate Governance
  • Contact Us
• Contact Us

Partners

Partnerships
GSK
AstraZeneca

Agreements
Novartis
NIH

Partners

Dynavax has partnerships with major pharmaceutical companies and funding agreements to support our discovery and development programs.  These agreements include:

Our TLR inhibitor therapies are partnered under a potential $800 million worldwide strategic alliance with GlaxoSmithKline, one of the world’s leading research-based pharmaceutical and healthcare companies. 

Our asthma/COPD therapies are partnered under a potential $136 million global agreement with AstraZeneca, an industry leader in products for respiratory diseases.

Our Universal Flu vaccine is under a global supply and option agreement with Novartis, a leader in influenza vaccines, and is partially funded by NIH grants.